A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.

J Kozal, Michael; Lupo, Sergio; DeJesus, Edwin; Molina, Jean-Michel; McDonald, Cheryl; Raffi, Francois; Benetucci, Jorge; Mancini, Marco; Yang, Rong; Wirtz, Victoria; Percival, Lisa; Zhang, Jenny; Zhu, Li; Arikan, Dilek; Farajallah, Awny; Nguyen, Bach-Yen; Leavitt, Randi; McGrath, Donnie; Lataillade, Max; Spartan Study Team, The

doi:10.1310/hct1303-119

Public

A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.

Shared by NobleBlocks on Sep 8, 2026 • 11:23 AM UTC

Authors:

Michael J Kozal

Sergio Lupo

Edwin DeJesus

Abstract

BACKGROUND: Nucleoside and ritonavir (RTV) toxicities have led to increased interest in nucleoside reverse transcriptase inhibitors (NRTIs) and RTV-sparing antiretroviral regimens. SPARTAN was a multicenter, randomized, open-label, noncomparative pilot study evaluating the efficacy, safety, and resi...

Discussions